Abstract: Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a composition comprising a testosterone source, an aromatase inhibitor, and an estriol source. Also presented herein is the surprising discovery that exposing a subject to the compositions disclosed herein can increase a subject's longevity, survival time, life span, and health span, as well as treat Alzheimer's disease.

Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.

Abstract: This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.

Abstract: Methods for stimulating neural repair and remyelination and for treating a myelin related disorder in a subject are described. The methods include administering to a subject in need of treatment an effective amount of anacardic acid having the formula (I) of claim 1 or a pharmaceutically acceptable salt thereof.

Abstract: An ion channel blocker for treatment and/or prevention of hepatic fibrosis is provided. Based on the fact that the activation of hepatic stellate cells is an important link in anti-hepatic fibrosis, it is found that gliclazide has the effect of inhibiting the activation of hepatic stellate cells by in vitro and in vivo experiments. Further exploration reveals that gliclazide mainly inhibits the activation of hepatic stellate cells by inhibiting autophagy pathways, and thus the gliclazide can be used to prepare medicaments for treatment and/or prevention of hepatic fibrosis.

Abstract: The present invention discloses a pharmaceutical composition including a cannabinoid and a transient receptor potential cation channel (TRP) ligand, and methods of using same, such as for treating a subject afflicted with a cell proliferation related disease, or alleviating a symptom associated therewith.

Abstract: A pharmaceutical formulation contains a particulate porous sorbent selected from the group having aluminosilicates and their salts, with a neutral or basic pH and with a particle size in the range of 50 to 800 ?m, on which a mixture of polyoxyethylene sorbitan monooleate (Polysorbate 80) with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC and D8-THC is applied. The formulation improves bioavailability and releases profile of the cannabinoids.

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Abstract: Methods are provided for the treatment or prevention of metastasis by the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a cell impermeable ENPP1 inhibitor to treat or prevent metastasis. Aspects of the methods include administering to a subject in need thereof a therapeutically effective amount of an immune checkpoint inhibitor, a chemotherapeutic agent, and/or radiation treatment, in combination with a therapeutically effective amount of a cell impermeable ENPP1 inhibitor to treat or prevent metastasis.

Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

Abstract: The present invention provides an antimicrobial composition comprising: (i) one or more water soluble organosilanes at a concentration of about 0.01% to about 0.4% w/v; (ii) one or more quarternary ammonium compounds at a concentration of about 0.01% to 0.5% w/v; and (iii) one or more non-ionic or amphoteric or sarcosine anionic surfactants at a concentration of about 0.05% to about 1% w/v. Methods of making the composition and methods of treating and/or preventing a skin and/or wound infection using the composition are also provided.

Abstract: Disclosed herein are pollygalloyl compounds of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), or (XI), including pharmaceutically acceptable salts thereof, and methods and uses thereof. Compounds disclosed herein may be provided in a kit, including a solubilizer for dissolving the compound or composition as described herein and a saline solution. Also disclosed herein are methods for delivery of a therapeutic solution to a blood vessel.

Abstract: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: [In the formulas, each of formula (III) and formula (IV) represents an ?-anomer or a ?-anomer; each of R1, R3, and R4 is —OH or —OAc; R2 is a halogen atom, —OH, or —OAc; and R5 is —CH3, —C?CH, —C?CCH3, or —CH2C?CH.

Abstract: Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF-2 receptor. The agonist ligand of IGF-2 receptor may be IGF-2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.

Abstract: The present invention relates to a method of identifying an anti-aging compound. The present invention further relates to a method of preventing or treating aging in a patient and to a compound for use in a method of preventing or treating aging in a patient. Furthermore, the present invention relates to a method of determining if a patient is likely to respond to a treatment with an anti-aging compound.

Abstract: The present invention relates to promoters for differentiation into chondrocytes, chondrocyte proliferation promoter, and cartilaginous matrix production promoter, each containing a glycoside of liquiritigenin. According to the present invention, promoters for differentiation into chondrocytes, promoters for proliferation of chondrocytes, and promoters for cartilaginous matrix production, that are superior in the stability and safety, have a superior promoting action on differentiation into chondrocytes, a superior promoting action on proliferation of chondrocytes, and a superior promoting action on cartilaginous matrix production, and effective for regeneration of cartilage and further, prophylaxis or improvement of symptoms and diseases caused by the damage and inflammation of cartilage, or symptoms and diseases showing the loss of cartilage such as osteoarthritis and the like.

Abstract: The present disclosure describes methods of treating a hepatitis C virus (HCV) infection in a patient in need thereof by orally administering to the patient a therapeutically effective amount of a pharmaceutical composition, which may include one or more of compounds disclosed herein. The methods of treating the HCV infection in the patient may result in clearance of the HCV infection as measured by sustained virologic response.

Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.

Abstract: This invention relates to novel microRNA-29 (miR-29) compounds, compositions comprising the same, and their use in therapy. In particular, provided herein are miR-29 compounds and compositions that are particularly effective and safe in the treatment of diseases that involve localised collagen dysregulation, such as tendon damage including tendinopathy, and tissue fibrosis including Peyronie's disease and Dupuytren's disease. Also provided are advantageous dosages and treatment regimens for miR-29 compounds.

Abstract: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.

Abstract: A method for treating or inhibiting a neurological disease, disorder or condition, comprises administering dextran sulfate, or a pharmaceutically acceptable salt thereof, to a subject to treat or inhibit the neurological disease, disorder or condition.

Abstract: The present invention relates to a condensation product, obtained or obtainable by the reaction of phenol, formaldehyde, sulfuric acid and urea, or a pharmaceutical composition comprising the same for use in a method for the prevention or treatment of Coronavirus disease 2019 (COVID-19) and/or for the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, to a pharmaceutical set comprising such a pharmaceutical composition for the same use and to such a pharmaceutical composition or pharmaceutical set.

Abstract: Disclosed is a method for treating oxidative stress or inflammation which comprises administering to a subject suffering from oxidative stress or inflammation a therapeutically effective amount of sodium thiosulfate.

Abstract: Neuroprotective preparations (formulations) employing the synergistic, neurotrophic benefits of nutritional lithium with bioavailable magnesium (FIG. 1). The biological synergism of lithium and magnesium is further enhanced with a proprietary base of synergistic, neurotrophic nutrients. A highly-effective, trans-mucosal, delivery system is included to provide exceptional bioavailability of a palatable, convenient intra-oral preparation, which saturates the vascular tissue in the oral cavity for efficient absorption. Additionally, methods of use are described, allowing for effective, safe, and convenient use of this novel, neuroprotective, antioxidant, anti-inflammatory preparation for humans and animals.

Abstract: The present invention relates to an ophthalmological composition containing zinc chloride (A) and a polyvinyl-based polymer compound (B).

Abstract: The present invention provides methods for using an anionic manganese oxide (MnO) nanoparticle-based nucleic acid scavenger to (1) inhibit viral infection of cells, (2) reduce or inhibit a viral infection of a subject, and (3) reduce viral infection induced inflammation in a subject.

Abstract: The present application discloses an antibody, or fragment thereof, for the diagnosis, treatment or prevention of cancers wherein the antibody specifically binds to the PSMGFR peptide (SEQ ID NO:2) or a fragment thereof of the peptide.

Abstract: The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a first CAR that binds to a first antigen and a second CAR comprising a CD3? intracellular signaling domain that binds to a second antigen, and methods of use in treating cancers, such as solid tumors and hematological malignancies.

Abstract: Aspects of the present invention relate to the use the growth factors such as e.g., cytokines IL-2 and IL-12 for T-cell activation whereby the growth factor(s) is/are expressed by cells comprising synthetic chromosomes. The growth factor(s) is/are desirably under controllable expression from a synthetic chromosome. By approaches described herein, one can control an immune response to treat or inhibit a disease such as a cancer. The control may be provided by inducing expression of the growth factor(s), wherein expression level(s) can be fine-tuned. If more than one growth factor is expressed, the levels can be individually controlled so that the desired concentrations of each growth factor are obtained.

Abstract: A method is provided for treating cancer in an individual, the method comprising culturing patient derived tumor organoids (PDO) with cognate immune cells with or without the presence of one or more direct or indirect T cell activating agents; expanding T cells following activation; and administering the activated T cells to the individual.

Abstract: The present invention relates to chimeric antigen receptors (CARs), particularly CARs expressed in immune cells (e.g. Tregs) and their use in therapy. In particular, the invention provides a CAR comprising an antigen recognition domain that specifically binds to TREM2.

Abstract: This invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for the mutated human CTNNB1S37F. The inventive TCR can recognize the HLA-A2 restricted mutant CTNNB1S37F peptide (YLDSGIHFGA) but cannot recognize the wild-type CTNNB1S37 peptide (YLDSGIHSGA). The inventive TCR can also be activated by tumor cells harboring a mutated human CTNNB1S37F in the context of HLA-A2. The invention further provides related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells and pharmaceutical compositions relating to the TCR of the invention. Methods of treating or preventing cancer in a mammal are further provided by the invention.

Abstract: Provided herein are compositions and methods for the treatment of cancers using modified TILs, wherein the modified TILs include one or more immunomodulatory agents (e.g., cytokines) associated with their cell surface. The immunomodulatory agents associated with the TILs provide a localized immunostimulatory effect that can advantageously enhance TIL survival, proliferation and/or anti-tumor activity in a patient recipient. As such, the compositions and methods disclosed herein provide effective cancer therapies.

Abstract: The invention relates to rejuvenated hematopoietic stem cells and methods of use.

Abstract: The present invention discloses a mesenchymal stem cell treated by at least two of cytokines IL4, IL21, and IL27, an exosome and use thereof. The present invention relates to the technical field of biomedicine. The treatment way is as follows: treating and stimulating a mesenchymal stem cell by stages with a complete medium containing the cytokine composition to obtain a capacitated mesenchymal stem cell; and then replacing with a basal medium for starvation treatment to obtain the capacitated exosome. The mesenchymal stem cell obtained after being pretreated with the cytokine composition and an exosome thereof provided in the present invention can exert a stronger immune modulating effect and thus, can be used for the treatment of immune diseases better.

Abstract: Therapeutic chondrisome compositions and related methods are described.

Abstract: The present disclosure relates to a DNA construct, and a strain into which a recombinant vector comprising the DNA construct has been introduced. The DNA construct according to the present disclosure allows the expression of anticancer genes, operably linked downstream of first and second promoters, in a host strain or cell, to prevent and treat cancer. In addition, the DNA construct of the present invention can control the treatment of doxycycline so that the anticancer protein can be expressed at an appropriate dose for cancer treatment.

Abstract: A novel Akkermansia muciniphila strain is disclosed. The novel strain has effects of preventing or treating inflammatory or metabolic diseases. A composition containing the novel strain or a culture thereof are also disclosed. The novel strain, cultures thereof, or compositions containing the novel strain and/or cultures thereof are suitable to use in methods of preventing or treating inflammatory or metabolic diseases.

Abstract: According to the invention there is provided an antimicrobial agent for use in maintaining or re-establishing a healthy genital microbiome, wherein the antimicrobial agent is a predatory bacterium.

Abstract: The present invention provides a method of inhibiting a viral respiratory disease, comprising: administering to a subject, in need thereof, an effective amount of L. reuteri strain 3632 and/or strain 3630, wherein L. reuteri strain 3632 and/or strain 3630 secrete mersacidin.

Abstract: Generally, the present disclosure contemplates engineered vectors, organisms (e.g., bacteria or bacteriophage) containing the same, and methods for treating the gut of mammalian species by providing the organism containing the engineered vector to the gut of a mammal. Example engineered organisms can include one or more genes isolated from microbial populations for promoting isoflavone metabolism.

Abstract: The present invention relates to genetically modified Bacillus subtilis, compositions, and uses thereof in production of biomolecules and heterologous proteins and for delivery of biomolecules and heterologous proteins in animals and associated methods for improving animal health.

Abstract: Described herein is a method of improving the inhibitory profile of Streptococcus salivarius comprising formulating the S. salivarius in a composition comprising an effective amount of a supplemental saccharide. Also described herein are compositions comprising Streptococcus salivarius and supplemental saccharide, methods of inhibiting microorganisms using such compositions, therapeutic formulations comprising such compositions, and methods of treating or preventing diseases using such compositions and therapeutic formulations.

Abstract: Provided herein is a product comprising three bacterial strains that are Lactobacillus fermentum NCIMB 5221, Lactobacillus plantarum NCIMB 8826 and Bifidobacteria longum spp. infantis NCIMB 7022SS.

Abstract: The present invention relates to the technical field of microorganisms, in particular to a Bifidobacterium animalis subsp. lactis ATM-209 (GOLDGUT-BB18) inhibiting Helicobacter Pylori and an application thereof. The Bifidobacterium animalis subsp. lactis ATM-209 (GOLDGUT-BB18) provided by the present invention is preserved in China General Microbiological Culture Collection Center of China Committee for Culture Collection of Microorganisms, with a preservation number of CGMCC No. 25896. The strain has good acid tolerance, and can well adapt to a gastric environment; the strain has an obvious effect for inhibiting the growth of Helicobacter Pylori, can inhibit the in-vivo colonization of the Helicobacter Pylori in an animal experiment and relieve the inflammation caused by Helicobacter Pylori infection, and has broad application prospects in clinical prevention, treatment and inhibition of diseases related to Helicobacter pylori infection and gastrointestinal health food.

Abstract: The present disclosure relates to heat-treated Limosilactobacillus fermentum LM1020 for preventing hair loss and promoting hair growth, and more particularly, to heat-treated Limosilactobacillus fermentum LM1020 for preventing hair loss and promoting hair growth by promoting the proliferation of dermal papilla cells and a composition containing the same. Heat-treated Limosilactobacillus fermentum LM1020 of the present disclosure and a composition containing the same promotes the proliferation of dermal papilla cells, has excellent 5?-reductase-1 inhibitory activity, and promotes the expression of FGF7, FGF10, and EGF, which are growth factors, and thus have the effect of effect of preventing hair loss and promoting hair growth. The subject cell line referred to as Lactobacillus fermentum LM1020 has the International Depositary Authority accession number KCCM12918P, having been deposited on Dec. 23, 2020.

Abstract: The present disclosure provides a probiotics of PTA22 from rabbits, a nutritional composition for preparing food of rabbits and a composition for rabbits to degrade oxalic acid. Through this disclosure, the health of rabbits can be ensured and the resistance to pathogenic bacteria can be improved after rabbits consume the food containing PTA22. As well, the probiotic PTA22 can help rabbits reduce the risk of hypercalciuria and calculus.

Abstract: The present disclosure relates to methods of treating a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a Seneca Valley Virus (SVV) or a polynucleotide encoding the SVV viral genome to the subject, wherein the cancer is classified as sensitive to SVV infection based on the expression level of one or more genes in the cancer. Methods of selecting subjects for treatment are also provided herein.

Abstract: Artificial cervical fluid is disclosed that contains a mucilaginous extract from the okra plant. The mucilaginous extract can be produced using a hot aqueous extractant or cold extraction process followed by separation of larger particles from the extract. The extract finds many uses, for example as a sperm storage medium, a sperm freezing medium, a sexual lubricant, an artificial insemination medium, an in vitro fertilization medium, and methods for treating and/or preventing infection, replication, and transmission of viruses, such as sexually transmitted viruses.